Yu Sunakawa
Yu Sunakawa
St. Marianna University School of Medicine
Verified email at
Cited by
Cited by
Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors
J García-Foncillas, Y Sunakawa, D Aderka, Z Wainberg, P Ronga, ...
Frontiers in oncology 9, 849, 2019
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
JH Strickler, H Satake, TJ George, R Yaeger, A Hollebecque, ...
New England Journal of Medicine 388 (1), 33-43, 2023
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer
K Fujita, Y Ando, W Yamamoto, T Miya, H Endo, Y Sunakawa, K Araki, ...
Cancer chemotherapy and pharmacology 65, 251-258, 2010
Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network
Y Sunakawa, HJ Lenz
Current treatment options in oncology 16, 1-18, 2015
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
K Nakachi, M Ikeda, M Konishi, S Nomura, H Katayama, T Kataoka, ...
The Lancet 401 (10372), 195-203, 2023
Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans
K Fujita, T Sugiura, H Okumura, S Umeda, N Nakamichi, Y Watanabe, ...
Pharmaceutical research 31, 204-215, 2014
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
Y Sunakawa, J Furuse, T Okusaka, M Ikeda, F Nagashima, H Ueno, ...
Investigational new drugs 32, 104-112, 2014
CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in …
K Fujita, W Yamamoto, S Endo, H Endo, F Nagashima, W Ichikawa, ...
Cancer science 99 (5), 1049-1054, 2008
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated …
K Fujita, F Nagashima, W Yamamoto, H Endo, Y Sunakawa, K Yamashita, ...
Biological and Pharmaceutical Bulletin 31 (11), 2137-2142, 2008
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
Y Sunakawa, W Ichikawa, K Fujita, F Nagashima, H Ishida, K Yamashita, ...
Cancer chemotherapy and pharmacology 68, 279-284, 2011
First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
JH Strickler, H Satake, A Hollebecque, Y Sunakawa, P Tomasini, ...
Journal of Clinical Oncology 40 (36_suppl), 360490-360490, 2022
Genetic testing for UGT1A1* 28 and* 6 in Japanese patients who receive irinotecan chemotherapy
Y Akiyama, K Fujita, F Nagashima, W Yamamoto, H Endo, Y Sunakawa, ...
Annals of oncology 19 (12), 2089-2090, 2008
Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives
T Mizukami, N Izawa, TE Nakajima, Y Sunakawa
Drugs 79, 633-645, 2019
Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis …
Y Sunakawa, W Ichikawa, A Tsuji, T Denda, Y Segawa, Y Negoro, ...
Clinical colorectal cancer 16 (3), e171-e180, 2017
Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach
Y Ning, DL Hanna, W Zhang, A Mendez, D Yang, R El-Khoueiry, ...
Molecular cancer therapeutics 14 (10), 2401-2408, 2015
Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure
K Fujita, Y Masuo, H Okumura, Y Watanabe, H Suzuki, Y Sunakawa, ...
Pharmaceutical research 33, 269-282, 2016
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results …
Y Sunakawa, S Stintzing, S Cao, V Heinemann, C Cremolini, A Falcone, ...
Annals of Oncology 26 (12), 2450-2456, 2015
Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer
H Bando, Y Nakamura, H Taniguchi, M Shiozawa, H Yasui, T Esaki, ...
JCO Precision Oncology 6, e2100535, 2022
Plastin polymorphisms predict gender-and stage-specific colon cancer recurrence after adjuvant chemotherapy
Y Ning, A Gerger, W Zhang, DL Hanna, D Yang, T Winder, T Wakatsuki, ...
Molecular cancer therapeutics 13 (2), 528-539, 2014
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer
T Sasaki, K Fujita, Y Sunakawa, H Ishida, K Yamashita, K Miwa, S Saji, ...
International journal of clinical oncology 18, 735-742, 2013
The system can't perform the operation now. Try again later.
Articles 1–20